SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yun Liao, Bei Cai, Yi Li, Jie Chen, Binwu Ying, Chuanmin Tao, Min Zhao, Zhu Ba, Zhaoxia Zhang, Lanlan Wang, Association of HLA-DP/DQ, STAT4 and IL-28B variants with HBV viral clearance in Tibetans and Uygurs in China, Liver International, 2015, 35, 3
  2. 2
    Haiqing Wu, Gangde Zhao, Fangxing Qian, Kehui Liu, Jingdong Xie, Huijuan Zhou, Jie Xu, Yumin Xu, Yan Han, Qing Xie, Hui Wang, Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B, Liver International, 2015, 35, 2
  3. 3
    Hui Wang, Haiqing Wu, Shisan Bao, Xiaogang Xiang, Gangde Zhao, Kehui Liu, Fengdi Li, Yumin Xu, Baoyan An, Huijuan Zhou, Jie Lu, Qing Xie, Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population, Infection, Genetics and Evolution, 2015, 31, 161

    CrossRef

  4. 4
    Albert Friedrich Stättermayer, Peter Ferenci, Effect of IL28B genotype on hepatitis B and C virus infection, Current Opinion in Virology, 2015, 14, 50

    CrossRef

  5. 5
    Helen M. Lazear, Timothy J. Nice, Michael S. Diamond, Interferon-λ: Immune Functions at Barrier Surfaces and Beyond, Immunity, 2015, 43, 1, 15

    CrossRef

  6. 6
    Senem C. Karataylı, Mithat Bozdayı, Ersin Karataylı, Tuğba Öztürk, Abbas A. Husseini, Rabia Albayrak, Muhip Özkan, Zeynep Kalaylıoğlu, Kendal Yalçın, Kubilay Çınar, Ramazan İdilman, Cihan Yurdaydın, Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B, Liver International, 2015, 35, 3
  7. 7
    Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Ritsuzo Kozuka, Takehiro Hayashi, Madoka Toyama Kohmoto, Hisato Jomura, Hiroyasu Morikawa, Yoshiki Murakami, Susumu Shiomi, Norifumi Kawada, Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection, Journal of Interferon & Cytokine Research, 2015, 35, 8, 613

    CrossRef

  8. 8
    L. Boglione, J. Cusato, A. De Nicolò, G. Cariti, G. Di Perri, A. D'Avolio, Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon, Journal of Viral Hepatitis, 2015, 22, 3
  9. 9
    Xiaopan Wu, Weimei Shi, Jia Wu, Xilin Zhu, Kangmei Chen, Sujun Zheng, Zhuo Li, Zhongping Duan, Hui Li, Ying Liu, A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced, Liver International, 2014, 34, 10
  10. 10
    Tobias Boettler, Darius Moradpour, Robert Thimme, Fabien Zoulim, Bridging basic science and clinical research – The EASL Monothematic Conference on Translational Research in Viral Hepatitis, Journal of Hepatology, 2014, 61, 3, 696

    CrossRef

  11. 11
    Tao Zeng, WanWei Zhang, XiangTian Yu, XiaoPing Liu, MeiYi Li, Rui Liu, LuoNan Chen, Edge biomarkers for classification and prediction of phenotypes, Science China Life Sciences, 2014, 57, 11, 1103

    CrossRef

  12. 12
    Lin Cheng, Xiaowen Sun, Shun Tan, Wenting Tan, Yunjie Dan, Yi Zhou, Qing Mao, Guohong Deng, Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients, Hepatology Research, 2014, 44, 9
  13. 13
    Dayana Bravo, Carlos Solano, Estela Giménez, María José Remigia, Isabel Corrales, Paula Amat, David Navarro, Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients, Journal of Medical Virology, 2014, 86, 5
  14. 14
    Emre Yilmaz, Bulent Baran, Ozlem Mutluay Soyer, Mustafa Onel, Derya Onel, Asli Cifcibasi Ormeci, Suut Gokturk, Sami Evirgen, Filiz Akyuz, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu, Cetin Karaca, Effects of Polymorphisms in Interferon λ 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection, Clinical Gastroenterology and Hepatology, 2014, 12, 10, 1753

    CrossRef

  15. 15
    Ahmed A. Al-Qahtani, Mashael R. Al-Anazi, Ayman A. Abdo, Faisal M. Sanai, Waleed K. Al-Hamoudi, Khalid A. Alswat, Hamad I. Al-Ashgar, Nisreen Z. Khalaf, Nisha A. Viswan, Mohammed N. Al Ahdal, Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients, Liver International, 2014, 34, 7
  16. You have free access to this content16
    Jiannis Vlachogiannakos, George V. Papatheodoridis, HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?, Liver International, 2014, 34,
  17. 17
    Louis Jansen, Annikki de Niet, Femke Stelma, Erik P.A. van Iperen, Karel A. van Dort, Marjan J. Tempelmans Plat-Sinnige, R. Bart Takkenberg, Daniel J. Chin, A.H. (Koos) Zwinderman, Uri Lopatin, Neeltje A. Kootstra, Hendrik W. Reesink, HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels, Journal of Hepatology, 2014, 61, 4, 730

    CrossRef

  18. 18
    Christian Trépo, Henry L Y Chan, Anna Lok, Hepatitis B virus infection, The Lancet, 2014, 384, 9959, 2053

    CrossRef

  19. 19
    Chung-Feng Huang, Ming-Lun Yeh, Jia-Jung Lee, Mei-Chin Chen, Chia-Yen Dai, Jee-Fu Huang, Jer-Ming Chang, Hung-Chun Chen, Shang-Jyh Hwang, Wan-Long Chuang, Ming-Lung Yu, Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics, Hepatology International, 2014, 8, 2, 224

    CrossRef

  20. 20
    Q. Zhang, M. Lapalus, T. Asselah, C. Laouénan, R. Moucari, M. Martinot-Peignoux, I. Bieche, E. Estrabaud, S. De Muynck, N. Boyer, P. Bedossa, M. Vidaud, P. Marcellin, O. Lada, IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients, Journal of Viral Hepatitis, 2014, 21, 7
  21. 21
    Clark D. Russell, Samantha J. Griffiths, Jürgen Haas, Interferon Lambda Genetic Polymorphisms and Viral Infection: The Tip of the Iceberg?, DNA and Cell Biology, 2014, 33, 2, 60

    CrossRef

  22. 22
    S. J. Hadziyannis, A. Laras, E. Hadziyannis, Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection?, Alimentary Pharmacology & Therapeutics, 2014, 39, 10
  23. 23
    D. He, S. Guo, P. Zhu, S. Tao, M. Li, H. Huang, J. Wang, Y. Wang, M. Ding, Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients, Clinical Microbiology and Infection, 2014, 20, 10
  24. 24
    T. Heller, Y. Rotman, C. Koh, S. Clark, V. Haynes-Williams, R. Chang, R. McBurney, P. Schmid, J. Albrecht, D. E. Kleiner, M. G. Ghany, T. J. Liang, J. H. Hoofnagle, Long-term therapy of chronic delta hepatitis with peginterferon alfa, Alimentary Pharmacology & Therapeutics, 2014, 40, 1
  25. 25
    Suna Yapali, Nizar Talaat, Anna S. Lok, Management of Hepatitis B: Our Practice and How It Relates to the Guidelines, Clinical Gastroenterology and Hepatology, 2014, 12, 1, 16

    CrossRef

  26. 26
    Ubaldo Visco-Comandini, Daniele Lapa, Chiara Taibi, Claudio Angeletti, Maria Rosaria Capobianchi, Anna Rosa Garbuglia, No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance, Digestive and Liver Disease, 2014, 46, 4, 348

    CrossRef

  27. 27
    Tai-Chung Tseng, Jia-Horng Kao, Ding-Shinn Chen, Peginterferon α in the treatment of chronic hepatitis B, Expert Opinion on Biological Therapy, 2014, 14, 7, 995

    CrossRef

  28. 28
    W. P. Brouwer, M. J. Sonneveld, F. Tabak, K. Simon, Y. Cakaloglu, U. S. Akarca, S. Zeuzem, P. Ferenci, J. E. Heathcote, R. J. Knegt, A. Boonstra, B. E. Hansen, H. L. A. Janssen, Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2014, 40, 7
  29. 29
    Donatella Ieluzzi, Loredana Covolo, Francesco Donato, Giovanna Fattovich, Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy, Digestive and Liver Disease, 2014, 46, 5, 427

    CrossRef

  30. 30
    D. H. Lee, J.-H. Lee, Y. J. Kim, N. H. Park, Y. Cho, Y. B. Lee, J.-J. Yoo, M. Lee, Y. Y. Cho, W.-M. Choi, S. J. Yu, J.-H. Yoon, C. Y. Kim, H.-S. Lee, Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis, Journal of Viral Hepatitis, 2014, 21, 3
  31. 31
    A. F. Stättermayer, T. Scherzer, S. Beinhardt, K. Rutter, H. Hofer, P. Ferenci, Review article: genetic factors that modify the outcome of viral hepatitis, Alimentary Pharmacology & Therapeutics, 2014, 39, 10
  32. 32
    Vincent Zimmer, Frank Lammert, Role of genetics in diagnosis and therapy of acquired liver disease, Molecular Aspects of Medicine, 2014, 37, 15

    CrossRef

  33. 33
    Lucio Boglione, Jessica Cusato, Sarah Allegra, Isabella Esposito, Francesca Patti, Giuseppe Cariti, Giovanni Di Perri, Antonio D’Avolio, Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon, Antiviral Research, 2014, 102, 35

    CrossRef

  34. 34
    E. Galmozzi, M. Viganò, P. Lampertico, Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?, Alimentary Pharmacology & Therapeutics, 2014, 39, 6
  35. 35
    Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio, The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon, Journal of Infection, 2014, 69, 1, 81

    CrossRef

  36. 36
    K. Domagalski, M. Pawłowska, A. Zaleśna, M. Tyczyno, M. Skorupa-Kłaput, A. Tretyn, W. Halota, The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection, European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33, 11, 2025

    CrossRef

  37. 37
    Phunchai Charatcharoenwitthaya, Teerha Piratvisuth, Baseline and On-treatment Predictors of Chronic Hepatitis B Patients Receiving Pegylated Interferon Therapy in Asia, Current Hepatitis Reports, 2013, 12, 3, 165

    CrossRef

  38. 38
    W.-K. Seto, D. K.-H. Wong, M. Kopaniszen, P. Proitsi, P.-C. Sham, I. F.-N. Hung, J. Fung, C.-L. Lai, M.-F. Yuen, HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B, Clinical Infectious Diseases, 2013, 56, 12, 1695

    CrossRef

  39. 39
    G. Grammatikos, C. Sarrazin, IL28B und antivirale Therapie der Virushepatitis: Was bleibt?, Der Gastroenterologe, 2013, 8, 4, 322

    CrossRef

  40. 40
    Y. Liao, Y. Li, B. Cai, J. Chen, L. Wang, Lack of Association Between Interleukin 28B Polymorphisms and Spontaneous Viral Clearance in Hepatitis B Virus Patients, Clinical Infectious Diseases, 2013, 57, 4, 620

    CrossRef

  41. 41
    Tao Zeng, Shao-yan Sun, Yong Wang, Hailong Zhu, Luonan Chen, Network biomarkers reveal dysfunctional gene regulations during disease progression, FEBS Journal, 2013, 280, 22
  42. 42
    Nikolaus Jilg, Raymond T. Chung, One more piece in the interleukin 28B gene puzzle? The case of hepatitis B, Hepatology, 2013, 57, 3
  43. 43
    Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history, Expert Review of Anti-infective Therapy, 2013, 11, 5, 459

    CrossRef

  44. 44
    Michelle Martinot-Peignoux, Martine Lapalus, Cédric Laouénan, Olivier Lada, Ana Carolina Ferreira Netto-Cardoso, Nathalie Boyer, Marie Pierre Ripault, Roberto Carvalho-Filho, Tarik Asselah, Patrick Marcellin, Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA, Journal of Clinical Virology, 2013, 58, 2, 401

    CrossRef

  45. 45
    Wai-Kay Seto, Danny Ka-Ho Wong, James Fung, Fung-Yu Huang, Ching-Lung Lai, Man-Fung Yuen, Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy, Hepatology, 2013, 58, 3
  46. 46
    W.-K. Seto, D. K.-H. Wong, C.-L. Lai, M.-F. Yuen, Reply to Liao et al, Clinical Infectious Diseases, 2013, 57, 4, 622

    CrossRef

  47. 47
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico, Results of Treatment of Chronic Hepatitis B with Pegylated Interferon, Clinics in Liver Disease, 2013, 17, 3, 425

    CrossRef

  48. You have free access to this content48
    Pietro Lampertico, Mauro Viganò, Massimo Colombo, Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?, Liver International, 2013, 33,
  49. 49
    Toru Takahashi, Three cases of chronic hepatitis B in that interferon therapy was indicated, Kanzo, 2012, 53, 12, 853

    CrossRef